Sandhya Jain
Primary Care · Dearborn, MINPI 1023500972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 27.0% of the total. 2025 is the largest year on record at $1,110, 8.6 times the $129 reported in 2022.
Across 136 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$696
- Vanda Pharmaceuticals Inc.$267
- AbbVie$265
- Neurocrine Biosciences, Inc.$165
- Lundbeck LLC$127
- Pfizer$100
- plus $957 from 19 others
What the payments were for
- Food & beverage$2,577100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,577 in reported general payments places this provider in the 85th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 33 | $44,580 |
| JardianceEmpagliflozin | 32 | $38,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $30,628 |
| MounjaroTirzepatide | 22 | $22,769 |
| TrintellixVortioxetine Hydrobromide | 18 | $10,673 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $5,197 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $4,015 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,745 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,881 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,661 |
| Atorvastatin Calcium | 149 | $1,643 |
| Omeprazole | 88 | $1,168 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $698 |
| Ventolin HfaAlbuterol Sulfate | 11 | $668 |
| Levothyroxine Sodium | 64 | $593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $43 | $67,34955 claims |
| GSKTrelegy Ellipta | $16 | $30,62847 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $10,67318 claims |
| Indivior Inc.Suboxone | $94 | $5,19729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 primary care providers in Michigan.
Other primary care in Dearborn
- Kendall BerghoferDearborn$2K
- Chelsea PettitDearborn$2K
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.